Esperion hit by Amgen’s weak Repatha results
Esperion Therapeutics Inc ESPR 21.25% shares are trading lower by $5.10 (18 percent) at $24.55 in Friday’s session. It’s being dragged down by poor results from cholesterol drug testing that’s having a major negative impact on related stocks in the sector.
In another sympathy move, Regeneron Pharmaceuticals REGN 2.72% shares are trading lower by $19.50 at $373.09.
While Amgen (lower by roughly 6 percent) and Regeneron (lower by over 4 percent) are struggling to recover, Esperion was hit hardest and has been attempting to rebound.